The FDA recorded supplemental approvals dated today for tirzepatide, the GIP and GLP-1 receptor dual agonist, under both of its applications — Mounjaro (for type 2 diabetes) and Zepbound (for obesity), both from Eli Lilly.
The public approval record flags the supplements without stating what they cover, which can be anything from a manufacturing or labelling change to a new indication. On the information available this is a prompt to check the current prescribing information for a change, not confirmation of a new use. Tirzepatide is already marketed in India, so any labelling change is worth tracking for prescribers here.
- The FDA logged supplemental approvals for tirzepatide under both Mounjaro and Zepbound.
- Tirzepatide is a GIP/GLP-1 receptor dual agonist for type 2 diabetes and obesity.
- The record does not specify what the supplements change.
- Check the updated prescribing information rather than assuming a new indication.
Why it matters
A supplemental approval can quietly change dosing, safety wording or indication, so it is worth confirming against the current label.
Don't overread it
A supplemental approval is an administrative record; here it does not state a new indication, so it should not be read as one.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free